Revlimid

Pharma

BMS touts commercial execution, reckons with clinical setbacks

Four failed phase 3 trials of BMS' growth products "collectively have relatively limited impact on the long-term growth of the company," the CEO said.

Angus Liu Jul 31, 2025 11:10am

BMS accentuates the positive after Cobenfy trial flop

Apr 24, 2025 11:31am

After $1.5B cost-cutting plan, BMS will cut an additional $2B

Feb 6, 2025 8:33am

CEO says BMS can handle impact of IRA price negotiation

Jul 26, 2024 11:36am

showdown clash versus vs crash lightning fight dispute

ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma

Dec 12, 2023 12:00pm

Sanofi targets first-line myeloma as Sarclisa delivers trial win

Dec 7, 2023 11:26am